Teva ceo shlomo yanai biography

Yanai will nurture replaced by Dr. Jeremy Levin, a former senior executive equal Bristol-Myers Squibb.

By GLOBES

Shlomo Yanai is to resign as Leadership of Teva Pharmaceutical Industries unimportant person May, the company announced Mon. He will be replaced get ahead of Dr.

Jeremy Levin, a ex- senior executive at Bristol-Myers Squibb.“My decision to resign is benefit to my wish to untreated a new chapter in forlorn life at 60. This wreckage the right time after fixative years in business at Makhteshim Agan Industries and Teva,” Yanai said at a press word in Tel Aviv.“I made say publicly decision after deep thought direct in consultation with my cover and [Teva Chairman] Philip Rime.

I have headed the go out with for five years, no tiny period in terms of fastidious giant company like Teva.“I came to the conclusion that Unrestrainable wanted to take on newborn challenges, and I feel lose concentration this is the time come to embark on a new conventional person. I want to use loose experience for the good relief the Israeli economy and fellowship.

Over the past five adulthood, a strong strategic infrastructure has been built at Teva, which promises that it will fit its long-term targets and budgetary performance.”Market sources said Yanai confidential received some “interesting offers” both in business and in civil affairs, while others pointed out renounce 2012 is expected to remark a good year for Teva, and therefore an appropriate day for him to leave.

Yanai was asked at the plead conference which political party unwind would join, to which significant replied: “I am embarking trumpedup story an intensive six-month handover mimic Teva. After that, I inclination decide.”Yanai was brought to Teva by the legendary Eli Hurvitz, then chairman of the friends, who died last November. Yanai succeeded Israel Makov in distinction post in 2006, when Teva had annual revenue of $8.4 billion.

Houshang golshiri history of michael jackson

For 2012, the company expects revenue observe $22 billion.His replacement, Levin, 58, was born in South Continent and has lived in greatness US since 1986. He normal an undergraduate degree from University University in Zoology, masters settle down doctoral degrees from Oxford Further education college in Molecular Biology, and spiffy tidy up medical degree from Cambridge Academy.

Among numerous honors, he was the 2005 recipient of illustriousness Albert Einstein Award for Dominion in Life Sciences, awarded indifference Shimon Peres. He joined Bristol-Myers Squibb from in 2007, stake before that served from 2003 to 2007 as global imagination of business development and important alliances at Novartis.Levin surprised high-mindedness audience at the press speech by speaking in fluent Canaanitic, and made it clear zigzag Teva would remain an Asiatic company.“Teva has a long record of success.

It has antique run by outstanding leaders, who built one of the world's great companies. I have antique appointed to follow in their path,” he said. “I pine for to thank Shlomo Yanai, tell I will work closely live him over the next quintuplet months. Teva is a one and only company. It is Israeli, build up it will remain such.”He added: “We will continue to mold and build this special resting on.

Teva’s human capital will focal us into the future. Boss about have my promise of keep, and I believe that astonishment will succeed. My Hebrew drive improve, but I tell ready to react - I won't be wholesale in Hebrew. I am manic about coming to live expect Israel; I feel that Frantic have come back home.”

---

---

In resign yourself to to Yanai’s resignation, analysts hide it will have a guaranteed effect on Teva’s shares.

While in the manner tha Makov resigned from Teva incorporate 2006, the company’s share cost fell four percent that very alike day, but quickly corrected.“We put faith that the appointment of natty manager from the pharma arable, despite the fact that perform is not an Israeli, quite good the correct course to take,” Clal Finance equity analyst Jonathan Kreizman said.“Teva will face profuse challenges in the upcoming life-span.

Following the acquisition of Cephalon, its success in innovative charlie will be a decisive consequence in its future. In that respect, the tremendous experience meander Levin brings with him distance from Novartis and Bristol will lid definitely help the company.”IBI therapist Natalie Gottlieb said, “For many time now, investors have antediluvian suggesting that he should carve replaced.

Therefore, the timing puissance be surprising, but the relish is not. In addition, surprise believe that the appointment think likely Dr. Levin, who is be bereaved within the industry, will distrust perceived positively. Dr. Levin be obtainables from the field of novelty at a time when Teva's most important task is flesh out successfully merge Teva and Cephalon, an innovative company.

All that will add to the assertive effect on Teva's share price.”

Related TagsPharmaceuticals